Related Experiment Video
Updated: Sep 29, 2025
06:01
Prion Safety Laboratory Swipe Test
Published on: February 14, 2025
875
Investigating new treatments for Creutzfeldt-Jakob disease
1National Reference Center for Human Spongiform Encephalopathies, Department of Neurology, University Medical Center, Georg August University, Göttingen 37075, Germany.
The Lancet. Neurology
|March 19, 2022
Abstract
No abstract available in PubMed .
More Related Videos
09:50Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material
Published on: September 29, 2017
13.9K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
27.2K
Related Concept Videos
01:22Alzheimer's Disease: Treatment
276
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
276
01:24Parkinson's Disease: Treatment
415
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
415